^
    1d
    TNF-α and IFN-γ differentially regulate AML cell susceptibility to CD70-antibody-mediated cytotoxicity. (PubMed, J Immunother Cancer)
    CD70 is a promising target for NK cell-based immunotherapy in AML. However, IFN-γ-dependent upregulation of HLA molecules on AML cells contributes to resistance to ADCC. These findings underscore the need for rationale combination strategies in clinical trials to overcome this inducible immune escape mechanism.
    Journal • IO biomarker
    |
    IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha) • CD33 (CD33 Molecule) • CD70 (CD70 Molecule) • HLA-E (Major Histocompatibility Complex, Class I, E) • HLA-C (Major Histocompatibility Complex, Class I, C) • KIR2DS2 (Killer Cell Immunoglobulin Like Receptor, Two Ig Domains And Short Cytoplasmic Tail 2) • KLRC1 (Killer Cell Lectin Like Receptor C1)
    |
    PF-08046040
    4ms
    CULMINATE: A Study of Cusatuzumab Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia Who Are Not Candidates for Intensive Chemotherapy (clinicaltrials.gov)
    P2, N=103, Active, not recruiting, OncoVerity, Inc. | Trial completion date: Aug 2025 --> May 2026
    Trial completion date
    |
    azacitidine • cusatuzumab (ARGX-110)
    6ms
    Membrane-bound IL-15 co-expression powers a potent and persistent CD70-targeted TRuC T-cell therapy. (PubMed, Front Immunol)
    These findings characterize ADP-520 as a first-in-class, CD70-targeted, fratricide-resistant autologous TRuC T-cell therapy leveraging native TCR signaling combined with constitutive IL-15 signaling to impart T cells with enhanced persistence, tumor penetration, and antitumor efficacy. This makes ADP-520 a promising cell immunotherapy candidate for clinical development, with the potential to overcome hurdles intrinsic to the treatment of solid tumors.
    Journal • IO biomarker
    |
    CD70 (CD70 Molecule) • IL15 (Interleukin 15)
    6ms
    MP0533-CP101: Study of MP0533 in Patients Acute Myeloid Leukemia or Myelodysplastic Syndrome (clinicaltrials.gov)
    P1/2, N=249, Recruiting, Molecular Partners AG | N=70 --> 249 | Trial completion date: Dec 2027 --> Dec 2029 | Trial primary completion date: Dec 2025 --> Dec 2027
    Enrollment change • Trial completion date • Trial primary completion date
    |
    Venclexta (venetoclax) • azacitidine • Gazyva (obinutuzumab) • MP0533
    7ms
    SGNS70-101: A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies (clinicaltrials.gov)
    P1, N=178, Recruiting, Seagen, a wholly owned subsidiary of Pfizer | Trial completion date: Jun 2027 --> Jun 2028 | Trial primary completion date: Jun 2026 --> Jun 2027
    Trial completion date • Trial primary completion date
    |
    Venclexta (venetoclax) • azacitidine • PF-08046040
    8ms
    ELEVATE: Cusatuzumab in Combination With Background Therapy for the Treatment of Participants With Acute Myeloid Leukemia (clinicaltrials.gov)
    P1, N=61, Active, not recruiting, OncoVerity, Inc. | Trial completion date: May 2025 --> May 2026 | Trial primary completion date: May 2025 --> May 2026
    Trial completion date • Trial primary completion date
    |
    Venclexta (venetoclax) • azacitidine • cusatuzumab (ARGX-110)
    9ms
    SGNS70-101: A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies (clinicaltrials.gov)
    P1, N=178, Recruiting, Seagen, a wholly owned subsidiary of Pfizer | Trial completion date: Nov 2026 --> Apr 2027 | Trial primary completion date: Dec 2024 --> Apr 2026
    Trial completion date • Trial primary completion date
    |
    Venclexta (venetoclax) • azacitidine • PF-08046040
    9ms
    CULMINATE: A Study of Cusatuzumab Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia Who Are Not Candidates for Intensive Chemotherapy (clinicaltrials.gov)
    P2, N=103, Active, not recruiting, OncoVerity, Inc. | Trial completion date: Aug 2024 --> Aug 2025
    Trial completion date
    |
    azacitidine • cusatuzumab (ARGX-110)
    over1year
    CULMINATE: A Study of Cusatuzumab Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia Who Are Not Candidates for Intensive Chemotherapy (clinicaltrials.gov)
    P2, N=103, Active, not recruiting, OncoVerity, Inc. | Trial completion date: Aug 2023 --> Aug 2024
    Trial completion date
    |
    azacitidine • cusatuzumab (ARGX-110)
    over1year
    A Study Comparing Venetoclax and Azacitidine Plus Cusatuzumab to Venetoclax and Azacitidine in Newly Diagnosed AML Ineligible for Intensive Therapy (clinicaltrials.gov)
    P2, N=120, Recruiting, OncoVerity, Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Venclexta (venetoclax) • azacitidine • cusatuzumab (ARGX-110)
    over1year
    ELEVATE: Cusatuzumab in Combination With Background Therapy for the Treatment of Participants With Acute Myeloid Leukemia (clinicaltrials.gov)
    P1, N=61, Active, not recruiting, OncoVerity, Inc. | Phase classification: P1b --> P1 | Trial completion date: May 2024 --> May 2025 | Trial primary completion date: May 2024 --> May 2025
    Phase classification • Trial completion date • Trial primary completion date • Combination therapy
    |
    Venclexta (venetoclax) • azacitidine • cusatuzumab (ARGX-110)
    over1year
    The CD33xCD123xCD70 Multispecific CD3-Engaging DARPin MP0533 Induces Selective T Cell-Mediated Killing of AML Leukemic Stem Cells. (PubMed, Cancer Immunol Res)
    These studies show that the multispecific-targeting strategy used with MP0533 holds promise for improved selectivity towards LSCs and efficacy against clonal heterogeneity, potentially bringing a new therapeutic option to this group of patients with high unmet need. MP0533 is currently being evaluated in a dose-escalation phase 1 study in patients with relapsed or refractory AML (NCT05673057).
    Journal
    |
    CD123 (Interleukin 3 Receptor Subunit Alpha) • CD33 (CD33 Molecule) • CD70 (CD70 Molecule) • IL3RA (Interleukin 3 Receptor Subunit Alpha)
    |
    MP0533